European Commission approves Roche’s Tecentriq SC, the EU's first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types
Posted:
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has granted marketing authorisation for Tecentriq® SC (atezolizumab), the European Union (EU)’s first PD-(L)1 cancer immunotherapy for subcutaneous (under the skin) injection.
OpenAI is expanding ChatGPT's healthcare capabilities with a new integration that connects Epic electronic health records (EHRs) to ChatGPT for Healthcare and a plugin that gives care providers access to public healthcare data sources.
The Epic integration lets clinicians bring patient information into…
Updated migraine prevention guidance incorporates calcitonin gene-related peptide (CGRP)-targeted therapies and places greater emphasis on individualized treatment selection based on patient priorities.
Preventive therapy should be offered to those with at least 4 migraine days per month, at least 4 moderate-to-severe headache days per…
Attendees
Sponsors and Exhibitors
Contact us